Search

Cefazolin

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Pegunigalsidase alfa

While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by

Relebactam

[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. … Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam].

Vanadium

PI-0824

Currently, most doctors who treat patients with PV will prescribe high-dose steroids and drugs that suppress the immune system in an effort to decrease the production of these antibodies. … The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system.

Quizartinib

[A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … cytarabine consolidation, followed by a maintenance monotherapy resulted in a 22% reduction in the risk of death.

Fenbufen

Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation. … Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis.

Oxethazaine

[L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816] … Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at

Risankizumab

[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716]

Butalbital

Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition.